Intended for healthcare professionals

Letters Molnupiravir’s premature authorisation

Molnupiravir’s authorisation should be re-evaluated after the Panoramic trial is reported

BMJ 2022; 377 doi: https://doi.org/10.1136/bmj.o973 (Published 26 April 2022) Cite this as: BMJ 2022;377:o973